<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01985152</url>
  </required_header>
  <id_info>
    <org_study_id>HS-AZTP1a</org_study_id>
    <nct_id>NCT01985152</nct_id>
  </id_info>
  <brief_title>A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy Volunteers</brief_title>
  <official_title>A Placebo-Controlled, Phase I, Single-center Evaluation of the Single-dose Pharmacokinetics Study of Azilsartan Trimethylethanolamine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Pharmacokinetics and safety of Azilsartan
      Trimethylethanolamine in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To study the Pharmacokinetics of Azilsartan Trimethylethanolamine by assessment of drug concentration through blood sample analysis</measure>
    <time_frame>Pre-dose to 72 hours post-dosee</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse reactions</measure>
    <time_frame>Pre-dose to 72 hours post-dose</time_frame>
    <description>The trial shoud be terminated ，if more than a third of participants had grade 2 or more than 2 adverse reactions based on Common Terminology Criteria for Adverse Events(CTCAE) Version 4.02</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Health</condition>
  <arm_group>
    <arm_group_label>1.Azilsartan Trimethylethanolamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Azilsartan Trimethylethanolamine with 8.75mg,orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.Azilsartan Trimethylethanolamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Azilsartan Trimethylethanolamine with 17.5mg,orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.Azilsartan Trimethylethanolamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Azilsartan Trimethylethanolamine with 35mg,orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4.Azilsartan Trimethylethanolamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Azilsartan Trimethylethanolamine with 70mg,orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5.Azilsartan Trimethylethanolamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Azilsartan Trimethylethanolamine with 140mg,orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6.Azilsartan Trimethylethanolamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Azilsartan Trimethylethanolamine with 210mg,orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.Azilsartan Trimethylethanolamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Azilsartan Trimethylethanolamine with 280mg,orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-matching tablets, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan Trimethylethanolamine</intervention_name>
    <arm_group_label>1.Azilsartan Trimethylethanolamine</arm_group_label>
    <arm_group_label>2.Azilsartan Trimethylethanolamine</arm_group_label>
    <arm_group_label>3.Azilsartan Trimethylethanolamine</arm_group_label>
    <arm_group_label>4.Azilsartan Trimethylethanolamine</arm_group_label>
    <arm_group_label>5.Azilsartan Trimethylethanolamine</arm_group_label>
    <arm_group_label>6.Azilsartan Trimethylethanolamine</arm_group_label>
    <arm_group_label>7.Azilsartan Trimethylethanolamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females

          -  Aged from 18 years to 45 years

          -  Body mass index (BMI) 19 to 25kg/m2

        Exclusion Criteria:

          -  Has a known sensitivity to angiotensin II receptor blocker（ARB）

          -  With evidence of uncontrolled renal, hepatic, central nervous system, respiratory,
             cardiovascular, or metabolic dysfunction, in the opinion of the investigator or
             medical monitor

          -  Has known or suspected history of alcoholism or drug abuse or misuse

          -  With a history of laboratory results that show the presence of hepatitis B surface
             antigen (HBsAg), hepatitis C antibody (HCVAb), or human immunodeficiency virus (HIV)

          -  Pregnant,lactating，menstrual

          -  Vegetarian

          -  Postural hypotension

          -  Systolic blood pressure&lt;100mmHg，or&gt;130mmHg;and/or diastolic blood
             pressure&lt;70mmHg,or&gt;90mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Hou, Associate Chief Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>TEDA International Cardiovascular Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Hou, Associate Chief Physician</last_name>
    <phone>86-022-65209939</phone>
  </overall_contact>
  <location>
    <facility>
      <name>TEDA International Cardiovascular Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Hou, Associate Chief Physician</last_name>
      <phone>86-022-65209939</phone>
    </contact>
    <investigator>
      <last_name>Jie Hou, Associate Chief Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2013</study_first_submitted>
  <study_first_submitted_qc>November 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2013</study_first_posted>
  <last_update_submitted>November 7, 2013</last_update_submitted>
  <last_update_submitted_qc>November 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

